SCHEMBL1933706

SCHEMBL1933706

O=Cc1cnn2c(NC3CC3)cc(NC(=O)c3ccccc3F)nc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2B P67870 3/20 0.60
TYK2 P29597 4/20 0.43
CSNK2A2 P19784 2/20 0.41
CSNK2A1 P68400 2/20 0.41
KCNH2 Q12809 3/20 0.41
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
GAA P10253 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39
GLA P06280 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
HTR1A P08908 1/20 0.39
HTR1F P30939 1/20 0.39
MCHR1 Q99705 1/20 0.38
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2029885 0.84 CSNK2B (0.42) CSNK2BTYK2CSNK2A2CSNK2A1KCNH2
SCHEMBL2029894 0.84 CSNK2B (0.42) CSNK2BTYK2CSNK2A2CSNK2A1KCNH2
SCHEMBL1934028 0.80 CSNK2B (0.71) CSNK2BTYK2CSNK2A2CSNK2A1KCNH2
SCHEMBL1935407 0.79 CSNK2B (0.68) CSNK2BTYK2CSNK2A2CSNK2A1KCNH2
SCHEMBL2033022 0.78 CSNK2B (0.59) CSNK2BCSNK2A2CSNK2A1KCNH2DYRK3
SCHEMBL12645979 0.78 CSNK2B (0.41) CSNK2BTYK2CSNK2A2CSNK2A1KCNH2
SCHEMBL1934608 0.76 CSNK2B (1.00) CSNK2BTYK2CSNK2A2CSNK2A1KCNH2
SCHEMBL2032956 0.75 CSNK2B (0.63) CSNK2BCSNK2A2CSNK2A1
SCHEMBL12644986 0.75 CSNK2B (0.42) CSNK2BTYK2CSNK2A2CSNK2A1KCNH2
SCHEMBL2030284 0.75 CSNK2B (0.52) CSNK2BCSNK2A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2509602-B9 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS SENHWA BIOSCIENCES INC (TW) 2017-11-01 EP disclosed
EP-2509602-B1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS SENHWA BIOSCIENCES INC (TW) 2017-01-25 EP disclosed
US-9303033-B2 Pyrazolopyrimidines and related heterocycles as CK2 inhibitors SENHWA BIOSCIENCES, INC. (TW) 2016-04-05 US disclosed
US-8575177-B2 Pyrazolopyrimidines and related heterocycles as CK2 inhibitors SENHWA BIOSCIENCES, INC. (TW) 2013-11-05 US disclosed
EP-2509602-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS Cylene Pharmaceuticals, Inc. (US) 2012-10-17 EP disclosed
US-20110152240-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2011-06-23 US disclosed
WO-2011068667-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2011-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152240-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS CDK2, CKS2, CSNK2A1 CSNK2B 13/4885TYK2 63/4885CSNK2A2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.